An anthracycline antibiotic that has formula C27H29NO11.
Chemical ID:
MESH:D004317
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2,2'-(hydroxynitrosohydrazono)bis-ethanamine inhibits the reaction [Doxorubicin results in increased expression of SOD2 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [sesamin inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of SOD2 protein]]; [Probucol co-treated with Doxorubicin] results in increased activity of SOD2 protein; Carvedilol inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; Doxorubicin affects the expression of and affects the activity of SOD2 protein; Doxorubicin results in decreased expression of and results in decreased activity of SOD2 protein; Drugs, Chinese Herbal inhibits the reaction [Doxorubicin results in decreased activity of SOD2 protein]; epigallocatechin gallate affects the reaction [Doxorubicin affects the expression of and affects the activity of SOD2 protein]; Febuxostat inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; FNDC5 protein modified form inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of SOD2 protein]; FNDC5 protein modified form inhibits the reaction [Doxorubicin results in decreased expression of SOD2 mRNA]; GHRL protein inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; NFE2L2 protein promotes the reaction [FNDC5 protein modified form inhibits the reaction [Doxorubicin results in decreased expression of SOD2 mRNA]]; Probucol inhibits the reaction [Doxorubicin results in decreased expression of SOD2 mRNA]; Probucol inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; Propofol inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; sesamin inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of SOD2 protein]; SIRT6 protein inhibits the reaction [Doxorubicin results in decreased expression of SOD2 mRNA]; SOD2 protein inhibits the reaction [Doxorubicin affects the localization of NFATC3 protein]; SOD2 protein inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; SOD2 protein inhibits the reaction [Doxorubicin results in increased activity of CASP8 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Doxorubicin results in increased expression of SOD2 protein]
[Fluvastatin co-treated with Doxorubicin] results in increased expression of SOD2 protein; [TRP53 protein results in decreased expression of SOD2 mRNA] which results in increased susceptibility to Doxorubicin; Carbon Monoxide inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; epalrestat analog inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; epalrestat inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; FNDC5 protein inhibits the reaction [Doxorubicin results in decreased expression of and results in decreased activity of SOD2 protein]; naringin inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; Resveratrol inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; SIRT6 gene mutant form promotes the reaction [Doxorubicin results in increased expression of SOD2 mRNA]; sodium nitrate inhibits the reaction [Doxorubicin results in increased expression of SOD2 protein]
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Doxorubicin]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [SOD2 protein affects the reaction [Doxorubicin results in increased cleavage of CASP3 protein]]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [SOD2 protein affects the reaction [Doxorubicin results in increased cleavage of CASP9 protein]]; [benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone results in decreased activity of CASP9 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Doxorubicin]; Acetylcysteine affects the reaction [SOD2 protein results in decreased susceptibility to Doxorubicin]; Erythropoietin inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]; Glutathione affects the reaction [SOD2 protein results in decreased susceptibility to Doxorubicin]; IL1A protein promotes the reaction [Doxorubicin results in increased expression of SOD2 protein]; IL1B protein promotes the reaction [Doxorubicin results in increased expression of SOD2 protein]; PPARGC1A affects the reaction [Doxorubicin results in decreased expression of SOD2 protein]; PPARGC1A affects the reaction [Doxorubicin results in increased expression of SOD2 protein]; SOD2 protein affects the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; SOD2 protein affects the reaction [Doxorubicin results in increased cleavage of CASP9 protein]; SOD2 protein affects the reaction [Doxorubicin results in increased phosphorylation of MAPK1 protein]; SOD2 protein affects the reaction [Doxorubicin results in increased phosphorylation of MAPK3 protein]; TNF protein promotes the reaction [Doxorubicin results in increased expression of SOD2 protein]; TP53 protein affects the reaction [Doxorubicin results in increased expression of SOD2 mRNA]
